Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > XRAY PLUS RU KILLS LUNG CANCER
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1345)
•••
Comment by CancerSlayeron Jun 20, 2024 10:52am
180 Views
Post# 36097848

RE:XRAY PLUS RU KILLS LUNG CANCER

RE:XRAY PLUS RU KILLS LUNG CANCER
Tarbaby wrote: This is HUGE news that is being ignored. Lung cancer is No.1 tough to beat cancer.
Why not do a few more mouse implants of lung or breast cancers then destroy them to prove XRU works.
Then report it to news media. It will propel this company to the moon and catch deep pocket jv potential. A jv is the only way forward...imho


I agree Tarbaby...that particular PR/finding was the biggest news of the lot for me, especially considering that lung cancer is a leading cause of cancer death & the current standard of care (SOC) provides pretty dismal long-term survival at a reported 15+%.  And the adverse effects of SOC (chemo/radiotherapy followed by immunotherapy) plus the relatively "prolonged" treatment that's needed with immunotherapy make SOC a rather lengthy, grueling & costly endeavor that has very limited guarantees re: survival & quality of life.

One mouse actually became cancer-free after x-ray activated Rutherrin.  I also imagine one could possibly enhance efficacy by adjusting the X-Ray/Rutherrin dose, number of doses &/or type of external radiation (maybe one that is more targeted)?  The potential here simply seems amazing...i.e. wake up in the AM, get your injection of Rutherrin, wait a little bit, get a full-body X-Ray(s) (limited radiation), then go home same AM for coffee & a donut?  



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities